Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Exclusion Criteria

• •Known hepatitis B or C or human immunodeficiency virus (HIV), regardless of viral load
• •\* Testing for the purposes of enrollment is not mandatory, however a documented history of these infections will be exclusionary due to concerns for drug-drug interactions with antivirals and potential for increased risk of liver toxicity
• •Radiation for palliation of bony metastases within the preceding 2 weeks
• •Prior chemotherapy for metastatic castration-resistant prostate cancer (CRPC)
• •\* Immune therapy with sipuleucel-T is allowed, provided the last infusion was \>= 28 days prior to study therapy and there has been at least one documented PSA value rising after completion of sipuleucel-T therapy or progression of disease on imaging after sipuleucel-T
• •Malignancy (aside from prostate cancer) which required radiotherapy or systemic treatment within the past 5 years
• •* Superficial bladder cancer treated with intravesical therapy and currently in remission will not be an exclusion
• •* Skin cancers will not be an exclusion, except for melanoma with a thickness \> 1 mm
• •Concurrent medical condition which may increase the risk of toxicity, including:
• •* Pleural or pericardial effusion of any grade at the time of study entry
• •* Cardiac symptoms; any of the following should be considered for exclusion: \*\* Uncontrolled angina, congestive heart failure or myocardial infarction (MI) within (6 months)
• •* Diagnosed congenital long QT syndrome
• •* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) \*\* Prolonged QTc/f interval on pre-entry electrocardiogram (\> 450 msec)
• •* Hypokalemia or hypomagnesemia if it cannot be corrected prior to abiraterone administration
• •History of significant bleeding disorder unrelated to cancer, including:
• •* Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
• •* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
• •* Ongoing or recent (=\< 3 months) significant gastrointestinal bleeding
• •Prohibited treatments and/or therapies
• •* Should not be on any additional anti-cancer therapy except for luteinizing hormone-releasing hormone (LHRH) agonist/antagonist; specifically excluded medications include ketoconazole, estrogens, and anti-androgens
• •* Category I drugs that are generally accepted to have a risk of causing Torsades de pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib)
• •* Quinidine, procainamide, disopyramide
• •* Amiodarone, sotalol, ibutilide, dofetilide
• •* Erythromycin, clarithromycin
• •* Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
• •* Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
• •Prisoners or subjects who are involuntarily incarcerated
• •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness